Location |
Gene |
Polymorphism(s) |
Risk genotype |
Number of studies (cases) |
Size of effect
(95% CI) |
Reference |
1p36.3 |
MTHFR Methylenetetrahydrofolate reductase |
C677T |
TT |
40(11,162) |
1.14 (1.01-1.28) |
[70] |
1q23 |
F5 Factor V Leiden |
R506Q |
Q+ |
20(5,313) |
1.10(0.88-1.36) |
[69] |
1q42.2 |
AGTAngiotensinogen |
Met235Thr(M235T) |
TT |
21(4,001) |
1.19 (1.10-1.30) |
[64] |
2p24-p23 |
APOB Apolipoprotein B |
Gln4154Lys (Q4154L) |
LL |
14(1,796) |
1,73(1.19-2.50) |
[75] |
2p24-p23 |
APOB Apolipoprotein B |
Signal peptide Ins/Del |
DD |
22(6,007) |
1.19 (1.05-1.35) |
[75] |
7q21.3 |
PON1 Paraoxonase |
Q192R |
R192 |
44 (10,106) |
1.12 (1.07-1.16) |
[65] |
7q21.3-q22 |
PAI-1 Plasminogen activator inhibitor type 1 |
5G/4G |
4G4G |
7(2,813) |
1.20 (1.04-1.39) |
[73] |
7q36 |
NOS3 Nitric oxide synthase 3 |
Glu298Asp (E298D) |
DD |
14(6,036) |
1.31(1.13-1.51) |
[74] |
8p22 |
LPL Lipoprotein lipase |
Ser/Ter(S447X) |
X+ |
4(2,252) |
0.80(0.7-1.0) |
[66] |
11p11 |
F2 Prothrombin |
G20210A |
A+ |
19(4,944) |
1.21(0.99-1.58) |
[71] |
16q21 |
CETPCholesteryl estertransfer protein |
TaqIB |
B2B2 |
7(7,681) |
0.78(0.66-0.93) |
[72] |
17q21.32 |
ITGB3Platelet glycoprotein IIIa |
PL(A1/A2) |
A2+ |
34(6,173) |
1.13(1.02-1.26) |
[67] |
17q23.3 |
ACE Angiotensin I converting enzyme |
Insertion/Deletion |
DD |
43(14,292) |
1.22(1.11-1.35) |
[67] |
19q13.2 |
APOE Apolipoprotein E |
E2, E3, E4 |
e4 |
48(15,492) |
1.30(1.18-1.51) |
[68] |
|
